Several studies mainly in metastatic melanoma or renal cell carcinoma have been conducted over the last two decades combining IL-2 and various doses and techniques of RT, however, generally with a low efficacy or partial responses. This evidence concerns the gene IL2 and hereditary clear cell renal cell carcinoma.